Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jul;93(7):4420-4429.
doi: 10.1002/jmv.26996. Epub 2021 May 5.

Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms

Renuka Ananth Kalyan Kadali  1   2 , Ravali Janagama  3 , Sharanya Peruru  4 , Viswanath Gajula  5 , Rajasekhar R Madathala  6 , Nikhita Chennaiahgari  7 , Srikrishna V Malayala  8
Affiliations
Randomized Controlled Trial

Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms

Renuka Ananth Kalyan Kadali et al. J Med Virol. 2021 Jul.

Abstract

There are concerns regarding the side effects of the new coronavirus disease 2019 (COVID-19) mRNA-1273 vaccine among healthcare workers (HCWs) in the United States. The objective of the study was to investigate the side effects of the mRNA-1273 vaccine with detailed review of organ systems. A randomized, cross-sectional study using an independent online survey questionnaire was conducted to collect responses from HCWs. Of all participants, 87.8% (1116/1271) provided complete responses. Of them, 38.7% (432/1116) received the mRNA-1273 vaccine, among which, 89.35% were females; 425 of these 432 mRNA-1273 vaccine recipients (98.34%) reported at least one or more symptoms. The results were classified based on the frequency of symptoms reported postvaccination. Of these, 254/432 (58.8%) were able to continue their daily routine activities. 108/432 (25%) temporarily had trouble to perform daily activities, 120/432 (27.78%) required transient time off from work, 17/432 (3.94%) required help from an outpatient provider, 1/432 (0.23%) required help from emergency department, and none of them were hospitalized. Despite the wide array of self-reported symptoms, 97.02% of the HCWs did not intend to skip the second dose of vaccine. Among all the symptoms reported, localized pain, generalized weakness, headache, myalgia, chills, fever, nausea, joint pains, sweating, localized swelling at the injection site, dizziness, itching, rash, decreased appetite, muscle spasm, decreased sleep quality, and brain fogging were the most commonly reported symptoms (in descending order of occurrence). Most of the symptoms reported were nonlife threatening. Despite the wide array of self-reported symptoms, there appears to be a higher acceptance for this vaccine.

Keywords: COVID; COVID-19; Moderna; SARS-CoV-2; adverse events; mRNA-1273; side effects; symptoms; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they are no conflict of interests. The views in this article are those of the authors and not of their institutions, pharmaceutical companies, vaccine manufacturing companies, or the CDC, NIAID, NIH, and DHHS.

Figures

FIGURE 1
FIGURE 1
Classification of survey responses (attached below). HCWs, healthcare workers; mRNA, messenger RNA
See this image and copyright information in PMC

References

    1. Latinne A, Hu B, Olival KJ, et al. Origin and cross‐species transmission of bat coronaviruses in China. Nat Commun. 2020;11(1):4235. 10.1038/s41467-020-17687-3 - DOI - PMC - PubMed
    1. Ganyani T, Kremer C, Chen D, et al. Estimating the generation interval for coronavirus disease (COVID‐19) based on symptom onset data, March 2020. Euro Surveill. 2020;25(17):2000257. 10.2807/1560-7917.ES.2020.25.17.2000257 - DOI - PMC - PubMed
    1. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID‐19: a systematic review and meta‐analysis [published correction appears in Lancet Gastroenterol Hepatol. 2020 Jul;5(7):e6]. Lancet Gastroenterol Hepatol. 2020;5(7):667‐678. 10.1016/S2468-1253(20)30126-6 - DOI - PMC - PubMed
    1. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID‐19. Lancet Haematol. 2020;7(6):e438‐e440. 10.1016/S2352-3026(20)30145-9 - DOI - PMC - PubMed
    1. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID‐19. Am J Emerg Med. 2020;38(7):1504‐1507. 10.1016/j.ajem.2020.04.048 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances